Osteoporosis Treatment Pipeline Analysis 2025

According to DelveInsight's evaluation, globally, the Osteoporosis pipeline comprises over 30 key pharmaceutical firms continuously advancing more than 35 Osteoporosis treatment therapies, with analysis of Clinical Trials, Therapeutics, Mechanism of Action, Route of Administration, and Developments conducted by DelveInsight.

"Osteoporosis Pipeline Analysis, 2025" report by DelveInsight outlines comprehensive intelligence into the current clinical development scenario and growth prospects across the Osteoporosis Market.

The Osteoporosis Pipeline analysis encompasses in-depth commercial and clinical evaluation of the pipeline products from the preclinical developmental phase to the marketed phase. The analysis also covers a comprehensive description of the medication, including the mechanism of action of the therapeutic, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Primary Highlights from the Osteoporosis Pipeline Analysis:

https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

• Pharmaceutical firms across the globe are diligently advancing toward developing novel Osteoporosis treatment therapies with a considerable amount of success over recent years.

• Osteoporosis pharmaceutical firms operating in the treatment market include Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, among others, are creating therapies for Osteoporosis management.

• Emerging Osteoporosis investigational medications in the different phases of clinical trials include Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, among others, are anticipated to have a significant impact on the Osteoporosis market in the forthcoming years.

• In October 2025, Celltrion, Inc. revealed that the U.S. FDA has designated STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable biosimilars to the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications. These interchangeability designations were granted based on comprehensive comparative clinical data including pharmacokinetics, efficacy, safety, and immunogenicity in postmenopausal women with osteoporosis along with analytical evidence demonstrating similarity to the reference products.

• In April 2025, The City of Hope Medical Center initiated a Phase 1/2 clinical trial investigating whether the osteoporosis drug denosumab can enhance beta cell function in individuals with early type 1 diabetes. Amgen's denosumab is marketed as Prolia for osteoporosis and Xgeva for bone tumors. Additionally, the FDA has approved four sets of biosimilars, the latest being Fresenius's Conexxence/Bomyntra.

• In December 2024, GlycoNex, Inc. (GNX), a clinical-stage biotech company developing glycan-targeted cancer immunotherapies, disclosed that the first patient has been dosed in the Phase 3 trial of its denosumab biosimilar, SPD8. This pivotal investigation will evaluate SPD8 for osteoporosis treatment, with unblinded results anticipated in the second quarter of 2026.

Osteoporosis Background

Osteoporosis is a medical condition distinguished by weakened bones that become fragile and more susceptible to fractures. It occurs when bone density and quality decrease, often due to aging, hormonal changes, or nutritional deficiencies. Commonly affected areas include the hips, spine, and wrists. Early detection, lifestyle modifications, and medications can help strengthen bones, reduce fracture risk, and maintain overall skeletal health.

Access a Free Sample PDF Report to learn more about Osteoporosis Pipeline Therapeutic Evaluation- https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Emerging Osteoporosis Investigational Medications Under Different Phases of Clinical Development Include:

• Research programme: Lactocore

• RT-102: Rani Therapeutics

• SHR-1222: Jiangsu HengRui Medicine

• EB613: Entera Bio

• VOLT01: Levolta Pharmaceuticals, Inc.

• CT-P41: Celltrion

• TVB-009: Teva Pharmaceuticals

Osteoporosis Administration Method

The Osteoporosis pipeline analysis presents therapeutic evaluation of the pipeline medications by Administration Method. Products are classified under various administration routes, such as:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Osteoporosis Molecular Classification

Osteoporosis products are classified under various molecular categories, such as:

• Oligonucleotide

• Peptide

• Small molecule

Osteoporosis Pipeline Therapeutics Evaluation

• Osteoporosis Evaluation by Product Category

• Osteoporosis By Stage and Product Category

• Osteoporosis Evaluation by Administration Method

• Osteoporosis By Stage and Administration Method

• Osteoporosis Evaluation by Molecular Classification

• Osteoporosis by Stage and Molecular Classification

DelveInsight's Osteoporosis Analysis covers approximately 35+ products under different phases of clinical development including:

• Late-phase products (Phase III)

• Mid-phase products (Phase II)

• Early-phase product (Phase I)

• Preclinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Administration Method

Further Osteoporosis product details are provided in the analysis. Access the Osteoporosis pipeline analysis to learn more about the emerging Osteoporosis therapies https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Major Pharmaceutical Firms in the Osteoporosis Therapeutics Market Include:

Key pharmaceutical firms developing therapies for Osteoporosis include Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, Actavis PLC, among others.

Osteoporosis Pipeline Analysis:

The Osteoporosis pipeline analysis offers intelligence into:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Osteoporosis management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Osteoporosis Treatment.

• Osteoporosis key pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Osteoporosis investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Osteoporosis market.

The analysis is constructed using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, among others.

Access Sample PDF Report to learn more about Osteoporosis medications and therapies https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Osteoporosis Pipeline Market Drivers

• Rising geriatric population prone to low bone density, growing investments in research and development, increased Focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.

Osteoporosis Pipeline Market Obstacles

• However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.

Scope of Osteoporosis Pipeline Drug Intelligence

• Coverage: Global

• Key Osteoporosis Pharmaceutical Firms: Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, among others

• Key Osteoporosis Investigational Treatments: Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, among others

• Osteoporosis Therapeutic Evaluation: Osteoporosis current marketed and Osteoporosis emerging therapies

• Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market obstacles

Request for Sample PDF Report for Osteoporosis Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:

Kanishk

kkumar@delveinsight.com